BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has been given a consensus rating of “Buy” by the twenty-six brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, fifteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $109.32.

Several equities research analysts have recently weighed in on the company. BidaskClub cut BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Saturday. Piper Jaffray Companies reissued a “buy” rating and issued a $114.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday. Credit Suisse Group reissued an “outperform” rating and issued a $113.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday. Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Wedbush reissued an “outperform” rating and issued a $110.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, December 22nd.

In other BioMarin Pharmaceutical news, Director Elaine J. Heron sold 800 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $88.90, for a total value of $71,120.00. Following the transaction, the director now owns 38,385 shares in the company, valued at $3,412,426.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Eric Davis sold 1,200 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,750 shares of company stock worth $5,439,788. Corporate insiders own 1.85% of the company’s stock.

A number of large investors have recently made changes to their positions in BMRN. Vanguard Group Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 4.7% in the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock valued at $1,302,816,000 after purchasing an additional 642,623 shares in the last quarter. PDT Partners LLC bought a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $24,394,000. American Century Companies Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 64.5% in the third quarter. American Century Companies Inc. now owns 614,862 shares of the biotechnology company’s stock valued at $57,225,000 after purchasing an additional 241,183 shares in the last quarter. TCW Group Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 20.1% in the third quarter. TCW Group Inc. now owns 1,072,969 shares of the biotechnology company’s stock valued at $99,862,000 after purchasing an additional 179,879 shares in the last quarter. Finally, Pictet Asset Management Ltd. lifted its holdings in shares of BioMarin Pharmaceutical by 17.0% in the third quarter. Pictet Asset Management Ltd. now owns 1,134,622 shares of the biotechnology company’s stock valued at $105,599,000 after purchasing an additional 164,788 shares in the last quarter. Institutional investors and hedge funds own 99.15% of the company’s stock.

Shares of BioMarin Pharmaceutical (NASDAQ BMRN) traded down $0.66 on Friday, reaching $89.12. The company’s stock had a trading volume of 984,539 shares, compared to its average volume of 1,310,000. BioMarin Pharmaceutical has a fifty-two week low of $80.10 and a fifty-two week high of $100.51. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. The firm has a market cap of $15,540.00, a PE ratio of -107.37 and a beta of 1.81.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business had revenue of $334.18 million during the quarter, compared to analysts’ expectations of $347.38 million. During the same quarter in the prior year, the firm earned $0.02 EPS. The business’s revenue for the quarter was up 19.4% compared to the same quarter last year. equities analysts forecast that BioMarin Pharmaceutical will post -0.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Receives Average Recommendation of “Buy” from Analysts” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/20/biomarin-pharmaceutical-inc-bmrn-receives-average-recommendation-of-buy-from-analysts.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.